Lumigan in Germany: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in Germany under the regulatory framework of BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- Currency
- EUR
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in Germany
Germany classifies medications into rezeptpflichtig (prescription), apothekenpflichtig (pharmacy-only) and freiverkäuflich (general sale). The two-tier non-Rx system is unusual and widely used. Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in Germany follows the standard rules of BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte).
Pharmacy dispensing
German Apotheken are independent owner-pharmacist businesses by law, with strong professional standards. Statutory health insurance (gesetzliche Krankenversicherung) covers most prescription costs. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Mail-order pharmacies (DocMorris and others) are well-established in Germany for both Rx and OTC medications, operating under the same regulatory framework as bricks-and-mortar Apotheken. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in EUR
Retail pricing in Germany depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in Germany? ▾
Germany classifies medications into rezeptpflichtig (prescription), apothekenpflichtig (pharmacy-only) and freiverkäuflich (general sale). The two-tier non-Rx system is unusual and widely used. In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte).
Is generic Lumigan available in Germany? ▾
Authorised generics of Bimatoprost are typically available in Germany at a lower cost than branded Lumigan, with bioequivalence required by BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in EUR? ▾
Prices in EUR vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Germany.
Lumigan in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.